Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOLGA perioperative durvalumab, tremelimumab, and enfortumab vedotin in cisplatin-ineligible or cisplatin-refusing muscle-invasive bladder cancer
2023-507342-84-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial in bladder cancer and transitional cell carcinoma (TCC) comparing Durvalumab + Tremelimumab + Padcev with Durvalumab + Padcev (2 arms). Primary endpoints: Safety and tolerability in safety run-in and Event-free survival. Planned start Oct 2021; status: authorised.
02
Drugs
durvalumabtremelimumabenfortumab vedotin
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2023-507342-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507342-84-00.